The financial data announced by the company, where for Q22021, proceeded to an improved revision of its estimates for its revenues for the whole year, calculating them for 2021 at € 15.9 billion, highlight BioNTech as the success story of its total German industry.
BioNTech proves that investing in groundbreaking and innovative technologies such as the Covid-19 mRNA vaccine, developed jointly with US pharmaceutical company Pfizer, can make a major contribution to the country’s economy, highlighting a new area of investment. of the Biotechnology sector.
In addition, it gives a great advantage in highlighting research in Germany and Europe.
Also, the most important element is that all BioNTech production chains are based in Germany, highlighting the fact that all the profits announced by the company will absorb and distribute only in this EU member country.
